Who are recAP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fabrazyme (agalsidase beta), Pulmozyme®, Dornase alfa (Pulmozyme), DNase, rhDNAse, Dornase Alfa Inhalation Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recap.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

recAP — Competitive Intelligence Brief

recAP (recAP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant enzyme. Area: Immunology / Gastroenterology / Critical Care.

marketed Recombinant enzyme Lipopolysaccharide (LPS) and pathogen-associated molecular patterns (PAMPs) Immunology / Gastroenterology / Critical Care Biologic Live · refreshed every 30 min

Target snapshot

recAP (recAP) — AM-Pharma. recAP is a recombinant alkaline phosphatase that breaks down lipopolysaccharide (LPS) and other inflammatory mediators to reduce systemic inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
recAP TARGET	recAP	AM-Pharma	marketed	Recombinant enzyme	Lipopolysaccharide (LPS) and pathogen-associated molecular patterns (PAMPs)
Fabrazyme (agalsidase beta)	Fabrazyme (agalsidase beta)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy (ERT); recombinant enzyme	α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)
Pulmozyme®	Pulmozyme®	AO GENERIUM	marketed	Recombinant enzyme	Extracellular DNA
Dornase alfa (Pulmozyme)	Dornase alfa (Pulmozyme)	University of Jena	marketed	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
DNase	DNase	The Hospital for Sick Children	marketed	Recombinant enzyme	Deoxyribonucleic acid (DNA)
rhDNAse	rhDNAse	The Hospital for Sick Children	marketed	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
Dornase Alfa Inhalation Solution	Dornase Alfa Inhalation Solution	University of Missouri-Columbia	phase 3	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant enzyme class)

The Hospital for Sick Children · 2 drugs in this class
AO GENERIUM · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Protalix · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class
University of Jena · 1 drug in this class
AM-Pharma · 1 drug in this class
University of Missouri-Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). recAP — Competitive Intelligence Brief. https://druglandscape.com/ci/recap. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab